Telomir Pharmaceuticals, Inc | WebDisclosure

Basculer en Français

10703	Companies
228993	Keywords
157640	Articles
121599	Press releases

Headlines Articles Press releases Telomir Pharmaceuticals, Inc

Home
Companies
Telomir Pharmaceuticals, Inc

PRESS RELEASE

published on 06/05/2025 at 14:30, 1 year 1 month ago

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Telomir-1 treatment shows promising results in reversing aging hallmarks in a rare genetic disorder. Findings include restored gene control, extended telomere length, muscle and weight recovery, reduced oxidative stress, and 100% survival

Preclinical Data Genetic Disorder Telomir-1 Age-Reversal Telomere Length
BRIEF

published on 06/02/2025 at 14:35, 1 year 1 month ago

Telomir Pharmaceuticals to Advance Age-Reversal Research at BIO 2025

Rare Diseases IND Submission Telomir-1 Age-Reversal Preclinical Success
BRIEF

published on 06/02/2025 at 14:35, 1 year 1 month ago

Telomir Pharmaceuticals fera progresser la recherche sur l'inversion du vieillissement au BIO 2025

Maladies Rares Telomir-1 Inversion Du Vieillissement Soumission IND Succès Préclinique
PRESS RELEASE

published on 06/02/2025 at 14:30, 1 year 1 month ago

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Telomir Pharmaceuticals, Inc. to meet prospective partners at BIO International Convention 2025 to accelerate IND submission for Telomir-1, preparing for human dosing in 2026

BIO International Convention IND Submission Telomir-1 Telomir Pharmaceuticals Human Dosing
BRIEF

published on 05/29/2025 at 14:35, 1 year 1 month ago

Telomir-1 Shows Promise in Restoring Vision in AMD Animal Model

Telomir-1 Retina Regeneration AMD Model Zebrafish Study Vision Restoration
BRIEF

published on 05/29/2025 at 14:35, 1 year 1 month ago

Telomir-1 s'avère prometteur pour restaurer la vision dans un modèle animal de DMLA

Telomir-1 Régénération De La Rétine Modèle AMD Étude Sur Le Poisson Zèbre Restauration De La Vision
PRESS RELEASE

published on 05/29/2025 at 14:30, 1 year 1 month ago

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints
Telomir Pharmaceuticals reports positive preclinical results for oral drug Telomir-1 in age-related macular degeneration (AMD) model, showing vision restoration, retinal regeneration, and reduced oxidative stress

Preclinical Results Telomir-1 Telomir Pharmaceuticals Age-related Macular Degeneration Vision Restoration
BRIEF

published on 05/15/2025 at 14:05, 1 year 1 month ago

Telomir Pharmaceuticals Introduces Telomir-Ag2, Targeting Drug-Resistant Infections

Antimicrobial Resistance Healthcare Market Telomir Pharmaceuticals Silver(II) Stabilization Drug-resistant Pathogens
BRIEF

published on 05/15/2025 at 14:05, 1 year 1 month ago

Telomir Pharmaceuticals présente Telomir-Ag2, un médicament ciblant les infections résistantes aux médicaments

Résistance Aux Antimicrobiens Telomir Pharmaceuticals Stabilisation À L'argent (II) Agents Pathogènes Résistants Aux Médicaments Marché De La Santé
PRESS RELEASE

published on 05/15/2025 at 14:00, 1 year 1 month ago

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
Telomir Pharmaceuticals, Inc. announces Telomir-Ag2, a novel drug candidate addressing antimicrobial resistance with broad-spectrum activity, particularly against drug-resistant pathogens

Antimicrobial Resistance Drug Candidate Telomir Pharmaceuticals Inc. Telomir-Ag2 Silver(II) Complex

Accesswire

Published on 07/10/2026 at 00:10, 2 hours 39 minutes ago

Core Silver and Arcus Enter Into Definitive Arrangement Agreement for Business Combination
Published on 07/10/2026 at 00:10, 2 hours 39 minutes ago

Core Silver and Arcus Enter Into Definitive Arrangement Agreement for Business Combination
Published on 07/09/2026 at 23:05, 3 hours 44 minutes ago

Caldwell Reports Third Quarter Results and Announces Increase of Quarterly Dividend
Published on 07/09/2026 at 22:30, 4 hours 19 minutes ago

Rio Grande Resources Announces Equity Grants
Published on 07/09/2026 at 18:05, 8 hours 44 minutes ago

Sky Gold Corp Reports on Gold and Multi-Element Results from Drilling at Evening Star, Nevada

View all ACCESSWIRE

EQS Group

Published on 07/09/2026 at 19:25, 7 hours 24 minutes ago

LIGHTON CHANGES ITS GOVERNANCE WITH THE APPOINTMENT OF JEAN-PHILIPPE BAERT AS CHIEF EXECUTIVE OFFICER AND MARIE DE LAUZON AS CHAIR OF THE BOARD OF DIRECTORS
Published on 07/09/2026 at 19:25, 7 hours 24 minutes ago

LIGHTON FAIT ÉVOLUER SA GOUVERNANCE AVEC LA NOMINATION DE JEAN-PHILIPPE BAERT EN TANT QUE DIRECTEUR GÉNÉRAL ET DE MARIE DE LAUZON EN TANT QUE PRÉSIDENTE DU CONSEIL D’ADMINISTRATION
Published on 07/09/2026 at 18:50, 7 hours 58 minutes ago

NNS acquires shares in OCI
Published on 07/09/2026 at 18:46, 8 hours 2 minutes ago

OHB publishes results of the subscription offer and announces completion of the capital increase
Published on 07/09/2026 at 18:05, 8 hours 44 minutes ago

lePERMISLIBRE publie son chiffre d’affaires du premier semestre 2026

Les Echos

Published on 07/09/2026 at 18:48, 8 hours ago

Information relative au nombre total des droits de vote et d’actions composant le capital social
Published on 07/09/2026 at 18:47, 8 hours 1 minute ago

ICADE - CP - Modification du contrat de liquidite au 01 juillet 2026
Published on 07/09/2026 at 18:39, 8 hours 10 minutes ago

ICADE - CP - Bilan semestriel contrat de liquidité S1 2026
Published on 07/09/2026 at 18:00, 8 hours 49 minutes ago

SMTPC - Communiqué sur le Chiffre d'affaires du 2ème trimestre 2026
Published on 07/09/2026 at 18:00, 8 hours 49 minutes ago

Second-quarter 2026 activity: +7% (vs. Q2 2025)

View all LES ECHOS COMFI WIRE